EMILY PARKMAN: Open Payments
NPI 1568142479 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$890 in 47 payments from 22 companies in 2025. Trend: 2023 $534 · 2024 $1,135 · 2025 $890
Food & beverage: $890
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $147 |
| Novo Nordisk Inc | 4 | $88 |
| Otsuka America Pharmaceutical, Inc. | 3 | $59 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $57 |
| Astellas Pharma US Inc | 2 | $51 |
| Lilly USA, LLC | 3 | $48 |
| Xeris Pharmaceuticals, Inc. | 2 | $40 |
| Acella Pharmaceuticals, LLC | 2 | $40 |
| GlaxoSmithKline, LLC. | 2 | $37 |
| AstraZeneca Pharmaceuticals LP | 2 | $37 |
Products named: VRAYLAR, Wegovy, REXULTI, Kerendia, Veozah, GVOKE HYPOPEN, NP Thyroid 60, TRELEGY ELLIPTA.
Industry payments across TX — which companies pay providers there.
